Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Recro Gainesville Adds New Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Recro Gainesville Adds New Facility

Expands capabilities and adds high-potent processing

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Recro Gainesville has added a 24,000-sq.-ft. facility, which includes high-potent material processing space, near its existing 97,000- sq.-ft. contract development and manufacturing plant. The company is a wholly owned subsidiary of Recro Pharma, Inc., and a provider of pharmaceutical solid oral dose development and manufacturing services.
 
The expanded capabilities will allow Recro Gainesville to provide a broader range of services from formulation and development through clinical trial material (CTM) production for Phase I and beyond.
 
In addition, a specialized area within the new site will be opened by the end of the year to support clients with development through commercialization for high-potency compounds, a growing category of pharmaceuticals, which includes many immune modulation and anti-cancer agents.
 
“The new square footage allows for early feasibility studies, enabling clients to quickly determine the best formulation path forward at laboratory scale, and subsequent scale-up to the GMP manufacture of CTMs,” said Scott Rizzo, general manager of Recro Gainesville. “This added development capability will save our clients both time and resources.” 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics